Adding brain volume measures into response criteria in multiple sclerosis: the Río-4 score.
Beta-interferon
Brain atrophy
Brain volume
Multiple sclerosis
Treatment failure
Treatment response
Journal
Neuroradiology
ISSN: 1432-1920
Titre abrégé: Neuroradiology
Pays: Germany
ID NLM: 1302751
Informations de publication
Date de publication:
Jul 2021
Jul 2021
Historique:
received:
10
09
2020
accepted:
10
11
2020
pubmed:
26
11
2020
medline:
30
9
2021
entrez:
25
11
2020
Statut:
ppublish
Résumé
Brain volume changes (BVC) on therapy in MS are being considered as predictor for treatment response at an individual level. We ought to assess whether adding BVC as a factor to monitor interferon-beta response improves the predictive ability of the (no) evidence of disease activity (EDA-3) and Río score (RS-3) criteria for confirmed disability progression in a historical cohort. One hundred one patients from an observational cohort treated with interferon-beta were assessed for different cutoff points of BVC (ranged 0.2-1.2%), presence of active lesions (≥ 1 for EDA/≥ 3 for RS), relapses, and 6-month confirmed disability progression (CDP), measured by the Expanded Disability Status Scale, after 1 year. Sensitivity, specificity, and positive and negative predictive values for predicting confirmed disability progression at 4 years in original EDA (EDA-3) and RS (RS-3) as well as EDA and RS including BVC (EDA-4 and RS-4) were compared. Adding BVC to EDA slightly increased sensitivity, but not specificity or predictive values, nor the OR for predicting CDP; only EDA-3 showed a trend for predicting CDP (OR 3.701, p = 0.050). Adding BVC to RS-3 (defined as ≥ 2 criteria) helped to improve sensitivity and negative predictive value, and increased OR for predicting CDP using a cutoff of ≤ - 0.86% (RS-3 OR 23.528, p < 0.001; RS-4 for all cutoffs ranged from 15.06 to 32, p < 0.001). RS-4 showed areas under the curve larger than RS-3 for prediction of disability at 4 years. Addition of BVC to RS improves its prediction of response to interferon-beta.
Identifiants
pubmed: 33237430
doi: 10.1007/s00234-020-02604-8
pii: 10.1007/s00234-020-02604-8
doi:
Substances chimiques
Interferon-beta
77238-31-4
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
1031-1041Références
Filippi M, Rocca MA, Ciccarelli O, de Stefano N, Evangelou N, Kappos L, Rovira A, Sastre-Garriga J, Tintorè M, Frederiksen JL, Gasperini C, Palace J, Reich DS, Banwell B, Montalban X, Barkhof F (2016) MRI criteria for the diagnosis of multiple sclerosis: MAGNIMS consensus guidelines. Lancet Neurol 15:292–303. https://doi.org/10.1016/S1474-4422(15)00393-2
doi: 10.1016/S1474-4422(15)00393-2
pubmed: 26822746
pmcid: 4760851
Wattjes MP, Rovira A, Miller D et al (2015) Evidence-based guidelines: MAGNIMS consensus guidelines on the use of MRI in multiple sclerosis-establishing disease prognosis and monitoring patients. Nat Rev Neurol 11:597–606. https://doi.org/10.1038/nrneurol.2015.157
doi: 10.1038/nrneurol.2015.157
pubmed: 26369511
Thompson AJ, Banwell BL, Barkhof F, Carroll WM, Coetzee T, Comi G, Correale J, Fazekas F, Filippi M, Freedman MS, Fujihara K, Galetta SL, Hartung HP, Kappos L, Lublin FD, Marrie RA, Miller AE, Miller DH, Montalban X, Mowry EM, Sorensen PS, Tintoré M, Traboulsee AL, Trojano M, Uitdehaag BMJ, Vukusic S, Waubant E, Weinshenker BG, Reingold SC, Cohen JA (2018) Diagnosis of multiple sclerosis: 2017 revisions of the McDonald criteria. Lancet Neurol 17:162–173. https://doi.org/10.1016/S1474-4422(17)30470-2
doi: 10.1016/S1474-4422(17)30470-2
pubmed: 29275977
pmcid: 29275977
Tintore M, Rovira A, Rio J et al (2015) Defining high, medium and low impact prognostic factors for developing multiple sclerosis. Brain 138:1863–1874. https://doi.org/10.1093/brain/awv105
doi: 10.1093/brain/awv105
pubmed: 25902415
Brownlee WJ, Altmann DR, Prados F, Miszkiel KA, Eshaghi A, Gandini Wheeler-Kingshott CAM, Barkhof F, Ciccarelli O (2019) Early imaging predictors of long-term outcomes in relapse-onset multiple sclerosis. Brain 142:2276–2287. https://doi.org/10.1093/brain/awz156
doi: 10.1093/brain/awz156
pubmed: 31342055
Rio J, Castillo J, Rovira A et al (2009) Measures in the first year of therapy predict the response to interferon beta in MS. Mult Scler 15:848–853. https://doi.org/10.1177/1352458509104591
doi: 10.1177/1352458509104591
pubmed: 19542263
Giovannoni G (2015) Any evident MRI T2-lesion activity should guide change of therapy in multiple sclerosis—yes. Mult Scler 21:134–136. https://doi.org/10.1177/1352458514566261
doi: 10.1177/1352458514566261
pubmed: 25623249
Trapp BD, Peterson J, Ransohoff RM, Rudick R, Mork S, Bo L (1998) Axonal transection in the lesions of multiple sclerosis. N Engl J Med 338:278–285. https://doi.org/10.1056/NEJM199801293380502
doi: 10.1056/NEJM199801293380502
pubmed: 9445407
pmcid: 9445407
Pérez-Miralles F, Sastre-Garriga J, Tintoré M, Arrambide G, Nos C, Perkal H, Río J, Edo MC, Horga A, Castilló J, Auger C, Huerga E, Rovira A, Montalban X (2013) Clinical impact of early brain atrophy in clinically isolated syndromes. Mult Scler 19:1878–1886. https://doi.org/10.1177/1352458513488231
doi: 10.1177/1352458513488231
pubmed: 23652215
De Stefano N, Giorgio A, Battaglini M et al (2010) Assessing brain atrophy rates in a large population of untreated multiple sclerosis subtypes. Neurology 74:1868–1876. https://doi.org/10.1212/WNL.0b013e3181e24136
doi: 10.1212/WNL.0b013e3181e24136
pubmed: 20530323
Sastre-Garriga J, Ingle GT, Chard DT, Cercignani M, Ramió-Torrentà L, Miller DH, Thompson AJ (2005) Grey and white matter volume changes in early primary progressive multiple sclerosis: a longitudinal study. Brain 128:1454–1460. https://doi.org/10.1093/brain/awh498
doi: 10.1093/brain/awh498
pubmed: 15817511
Rovira A, Wattjes MP, Tintore M et al (2015) Evidence-based guidelines: MAGNIMS consensus guidelines on the use of MRI in multiple sclerosis-clinical implementation in the diagnostic process. Nat Rev Neurol 11:471–482. https://doi.org/10.1038/nrneurol.2015.106
doi: 10.1038/nrneurol.2015.106
pubmed: 26149978
Sastre-Garriga J, Ingle GT, Rovaris M, Tellez N, Jasperse B, Altmann DR, Benedetti B, Stevenson VL, Cercignani M, Leary SM, Barkhof F, Brochet B, Dousset V, Filippi M, Montalban X, Kalkers NF, Polman CH, Rovira A, Miller DH, Thompson AJ (2005) Long-term clinical outcome of primary progressive MS: predictive value of clinical and MRI data. Neurology 65:633–635. https://doi.org/10.1212/01.wnl.0000173061.12776.1f
doi: 10.1212/01.wnl.0000173061.12776.1f
pubmed: 16116134
Sormani MP, Arnold DL, De Stefano N (2014) Treatment effect on brain atrophy correlates with treatment effect on disability in multiple sclerosis. Ann Neurol 75:43–49. https://doi.org/10.1002/ana.24018
doi: 10.1002/ana.24018
pubmed: 24006277
Vidal-Jordana A, Sastre-Garriga J, Rovira A, Montalban X (2015) Treating relapsing-remitting multiple sclerosis: therapy effects on brain atrophy. J Neurol 262:2617–2626. https://doi.org/10.1007/s00415-015-7798-0
doi: 10.1007/s00415-015-7798-0
pubmed: 26041617
Pérez-Miralles FC, Sastre-Garriga J, Vidal-Jordana A, Río J, Auger C, Pareto D, Tintoré M, Rovira A, Montalban X (2015) Predictive value of early brain atrophy on response in patients treated with interferon beta. Neurol Neuroimmunol Neuroinflamm 2:e132. https://doi.org/10.1212/NXI.0000000000000132
doi: 10.1212/NXI.0000000000000132
pubmed: 26185778
Sormani MP, De Stefano N, Francis G et al (2015) Fingolimod effect on brain volume loss independently contributes to its effect on disability. Mult Scler 21:916–924. https://doi.org/10.1177/1352458515569099
doi: 10.1177/1352458515569099
pubmed: 25662353
Gasperini C, Prosperini L, Tintoré M, Sormani MP, Filippi M, Rio J, Palace J, Rocca MA, Ciccarelli O, Barkhof F, Sastre-Garriga J, Vrenken H, Frederiksen JL, Yousry TA, Enzinger C, Rovira A, Kappos L, Pozzilli C, Montalban X, de Stefano N, and the MAGNIMS Study Group (2019) Unraveling treatment response in multiple sclerosis: a clinical and MRI challenge. Neurology 92:180–192. https://doi.org/10.1212/WNL.0000000000006810
doi: 10.1212/WNL.0000000000006810
pubmed: 30587516
Imitola J, Racke MK (2015) Is no evidence of disease activity a realistic goal for patients with multiple sclerosis? JAMA Neurol 72:145–147. https://doi.org/10.1001/jamaneurol.2014.3860
doi: 10.1001/jamaneurol.2014.3860
pubmed: 25531742
Popescu V, Agosta F, Hulst HE, Sluimer IC, Knol DL, Sormani MP, Enzinger C, Ropele S, Alonso J, Sastre-Garriga J, Rovira A, Montalban X, Bodini B, Ciccarelli O, Khaleeli Z, Chard DT, Matthews L, Palace J, Giorgio A, de Stefano N, Eisele P, Gass A, Polman CH, Uitdehaag BMJ, Messina MJ, Comi G, Filippi M, Barkhof F, Vrenken H, on behalf of the MAGNIMS Study Group (2013) Brain atrophy and lesion load predict long term disability in multiple sclerosis. J Neurol Neurosurg Psychiatry 84:1082–1091. https://doi.org/10.1136/jnnp-2012-304094
doi: 10.1136/jnnp-2012-304094
pubmed: 23524331
Kappos L, De Stefano N, Freedman MS et al (2016) Inclusion of brain volume loss in a revised measure of ‘no evidence of disease activity’ (NEDA-4) in relapsing-remitting multiple sclerosis. Mult Scler 22:1297–1305. https://doi.org/10.1177/1352458515616701
doi: 10.1177/1352458515616701
pubmed: 26585439
Smith SM, De Stefano N, Jenkinson M, Matthews PM (2001) Normalized accurate measurement of longitudinal brain change. J Comput Assist Tomogr 25:466–475. https://doi.org/10.1097/00004728-200105000-00022
doi: 10.1097/00004728-200105000-00022
pubmed: 11351200
De Stefano N, Stromillo ML, Giorgio A et al (2016) Establishing pathological cutoffs of brain atrophy rates in multiple sclerosis. J Neurol Neurosurg Psychiatry 87:93–99. https://doi.org/10.1136/jnnp-2014-309903
doi: 10.1136/jnnp-2014-309903
pubmed: 25904813
Kappos L, Radue EW, O'Connor P, Polman C, Hohlfeld R, Calabresi P, Selmaj K, Agoropoulou C, Leyk M, Zhang-Auberson L, Burtin P, FREEDOMS Study Group (2010) A placebo-controlled trial of oral fingolimod in relapsing multiple sclerosis. N Engl J Med 362:387–401. https://doi.org/10.1056/NEJMoa0909494
doi: 10.1056/NEJMoa0909494
pubmed: 20089952
Havrdova E, Galetta S, Hutchinson M, Stefoski D, Bates D, Polman CH, O'Connor PW, Giovannoni G, Phillips JT, Lublin FD, Pace A, Kim R, Hyde R (2009) Effect of natalizumab on clinical and radiological disease activity in multiple sclerosis: a retrospective analysis of the Natalizumab Safety and Efficacy in Relapsing-Remitting Multiple Sclerosis (AFFIRM) study. Lancet Neurol 8:254–260. https://doi.org/10.1016/S1474-4422(09)70021-3
doi: 10.1016/S1474-4422(09)70021-3
pubmed: 19201654
Bevan CJ, Cree BA (2014) Disease activity free status: a new end point for a new era in multiple sclerosis clinical research? JAMA Neurol 71:269–270. https://doi.org/10.1001/jamaneurol.2013.5486
doi: 10.1001/jamaneurol.2013.5486
pubmed: 24395449
Rotstein DL, Healy BC, Malik MT, Chitnis T, Weiner HL (2015) Evaluation of no evidence of disease activity in a 7-year longitudinal multiple sclerosis cohort. JAMA Neurol 72:152–158. https://doi.org/10.1001/jamaneurol.2014.3537
doi: 10.1001/jamaneurol.2014.3537
pubmed: 25531931
Rio J (2015) Any evident MRI T2 lesion activity should guide change of therapy in multiple sclerosis: no. Mult Scler 21:132–133. https://doi.org/10.1177/1352458514565415
doi: 10.1177/1352458514565415
pubmed: 25583834
Vidal-Jordana A, Sastre-Garriga J, Pérez-Miralles F, Tur C, Tintoré M, Horga A, Auger C, Río J, Nos C, Edo MC, Arévalo MJ, Castilló J, Rovira A, Montalban X (2013) Early brain pseudoatrophy while on natalizumab therapy is due to white matter volume changes. Mult Scler 19:1175–1181. https://doi.org/10.1177/1352458512473190
doi: 10.1177/1352458512473190
pubmed: 23319072
Fisher E, Nakamura K, Lee JC, You X, Sperling B, Rudick RA (2016) Effect of intramuscular interferon beta-1a on gray matter atrophy in relapsing-remitting multiple sclerosis: a retrospective analysis. Mult Scler 22:668–676. https://doi.org/10.1177/1352458515599072
doi: 10.1177/1352458515599072
pubmed: 26238463
Rio J, Rovira A, Tintore M et al (2014) Evaluating the response to glatiramer acetate in relapsing-remitting multiple sclerosis (RRMS) patients. Mult Scler 20:1602–1608. https://doi.org/10.1177/1352458514527863
doi: 10.1177/1352458514527863
pubmed: 24622350
Vrenken H, Jenkinson M, Horsfield MA et al (2013) Recommendations to improve imaging and analysis of brain lesion load and atrophy in longitudinal studies of multiple sclerosis. J Neurol 260:2458–2471. https://doi.org/10.1007/s00415-012-6762-5
doi: 10.1007/s00415-012-6762-5
pubmed: 23263472
Giovannoni G, Turner B, Gnanapavan S, Offiah C, Schmierer K, Marta M (2015) Is it time to target no evident disease activity (NEDA) in multiple sclerosis? Mult Scler Relat Disord 4:329–333. https://doi.org/10.1016/j.msard.2015.04.006
doi: 10.1016/j.msard.2015.04.006
pubmed: 26195051
Uher T, Krasenky J, Sobisek L et al (2018) The role of high-frequency MRI monitoring in the detection of brain atrophy in multiple sclerosis. J Neuroimaging 28:328–337. https://doi.org/10.1111/jon.12505
doi: 10.1111/jon.12505
pubmed: 29485230
Sastre-Garriga J, Pareto D, Battaglini M et al (2020) MAGNIMS consensus recommendations on the use of brain and spinal cord atrophy measures in clinical practice. Nat Rev Neurol 16:171–182. https://doi.org/10.1038/s41582-020-0314-x
doi: 10.1038/s41582-020-0314-x
pubmed: 32094485
pmcid: 7054210